

IN THE CLAIMS:

1. (Currently amended) ~~An isolated~~ A biologically pure microorganism ~~strain~~, *Lactobacillus paracasei* GM-080, deposited at the China Center for Type Culture Collection under CCTCC No.: CCTCC M 204012.
2. (Currently amended) A composition comprising the biologically pure microorganism ~~strain~~ according to Claim 1.
3. (Currently amended) The ~~composition~~ method according to Claim ~~14 2~~, ~~which is used for stimulating IFN- γ secretion~~ wherein the allergy related disease is eczema.
4. (Currently amended) The ~~composition~~ method according to Claim ~~14 2~~, ~~which is used for treating allergy related disease~~ wherein the allergy related disease is atopic dermatitis.
5. (Currently amended) The ~~composition~~ method according to Claim ~~4 14~~, wherein the allergy related disease is ~~selected from the group consisting of airway hyperreactivity and inflammation, atopic dermatitis, allergic conjunctivitis, rhinitis, sinusitis, hypersensitive pneumonia, extrinsic allergic alveolitis, urticaria, eczema, anaphylaxis, angioedema, allergic and migraine headache, certain gastrointestinal disorders, and asthma~~.
6. (Currently amended) The ~~composition~~ method according to Claim ~~5 14~~, wherein the allergy related disease is asthma ~~airway hyperreactivity or inflammation~~.
7. (Currently amended) The ~~composition~~ method according to Claim ~~4 14~~, wherein the allergy related disease is rhinitis ~~associated with exposure to aeroallergen~~.
8. (Currently amended) The composition according to Claim 2, wherein the microorganism ~~strain~~ is live ~~or inactivated~~.
9. (Currently amended) The composition according to Claim ~~2 8~~, wherein the microorganism ~~strain~~ is inactivated.
10. (Currently amended) The composition according to Claim 2 which is in the form of a pharmaceutical composition, dietary supplement, food, or ~~the~~ a component thereof.
11. (Currently amended) A method for stimulating IFN- γ secretion in a subject comprising administering to said subject ~~with~~ a composition comprising the ~~isolated~~ biologically

pure microorganism according to Claim 1.

12. (Currently amended) The method according to Claim 11, wherein the microorganism ~~strain~~ is live ~~or inactivated~~.

13. (Currently amended) The method according to Claim ~~12~~ 11, wherein the microorganism ~~strain~~ is inactivated.

14. (Currently amended) A method for treating an allergy related disease in a subject comprising administering to said subject ~~with~~ a composition comprising the ~~isolated~~ biologically pure microorganism according to Claim 1.

15. (Currently amended) The method according to Claim 14, wherein the allergy related disease is selected from the group consisting of airway hyperreactivity and inflammation, atopic dermatitis, allergic conjunctivitis, rhinitis, sinusitis, hypersensitive pneumonia, extrinsic allergic alveolitis, urticaria, eczema, anaphylaxis, angioedema, allergic and migraine headache, certain gastrointestinal disorders, ~~or~~ and asthma.

16. (Original) The method according to Claim 15, wherein the allergy related disease is airway hyperreactivity or inflammation.

17. (Original) The method according to Claim 14, wherein the allergy related disease is associated with exposure to aeroallergen.

18. (Currently amended) The method according to Claim 14, wherein the microorganism ~~strain~~ is live ~~or inactivated~~.

19. (New) An *in vitro* culture comprising *Lactobacillus paracasei* GM-080, deposited at the China Center for Type Culture Collection under CCTCC No.: CCTCC M 204012.

20. (New) An *in vitro* culture comprising *Lactobacillus paracasei* GM-080, deposited at the China Center for Type Culture Collection under CCTCC No.: CCTCC M 204012 and one or more cells selected from the group consisting of splenocytes and peripheral blood mononuclear cells.

21. (New) The method according to Claim 14, wherein the microorganism is inactivated.
